Efficacy In Specific Patient SubgroupsUBX1325 generally outperformed aflibercept in the pre-specified subgroup entering the study with CST <400 microns, reflecting 60% of enrolled patients.

Long-term BenefitsThe Phase 2 BEHOLD study demonstrated statistically significant 48-week benefit in DME with mean change in BCVA +6.2 ETDRS letters from baseline, and 53% of UBX1325 treated patients without requirement of anti-VEGF rescue compared to 22% for sham.

Vision ImprovementUBX1325 patients gained 5.2 letters at week 24, and subsequently 5.5 letters at week 36, indicating vision improvement.

Bears Say

Imbalance In Study GroupsThere were considerably more Vabysmo (faricimab) patients in the UBX1325 group, compared to aflibercept, reflecting a relevant imbalance.

Specific Time Point UnderperformanceThe miss was driven entirely by the 20-week time point data, which was the only time point over the 36-week study where UBX1325 was inferior to aflibercept.

Study Endpoint MissThe previously announced primary endpoint miss for the Phase 2B ASPIRE study comparing UBX1325 and aflibercept in diabetic macular edema patients, not achieving non-inferiority at the average of weeks 20 and 24 primary analysis.

Unity Biotechnology News

UBX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Unity Biotech (UBX) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street analysts...

25d ago

UNBX

Unity Biotechnology Alters Voting Dynamics with New Stock

Unity Biotechnology ( ($UNBX) ) has provided an announcement. On July 22, 2025, Unity Biotechnology, Inc. entered into...

1M ago

UNBX

UNBX FAQ

What was Unity Biotechnology’s price range in the past 12 months?

Unity Biotechnology lowest stock price was $0.05 and its highest was $3.10 in the past 12 months.

What is Unity Biotechnology’s market cap?

Unity Biotechnology’s market cap is $1.25M.

When is Unity Biotechnology’s upcoming earnings report date?

Unity Biotechnology’s upcoming earnings report date is Nov 05, 2025 which is in 62 days.

How were Unity Biotechnology’s earnings last quarter?

Currently, no data Available

Is Unity Biotechnology overvalued?

According to Wall Street analysts Unity Biotechnology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Unity Biotechnology pay dividends?

Unity Biotechnology does not currently pay dividends.

What is Unity Biotechnology’s EPS estimate?

Unity Biotechnology’s EPS estimate is 0.

How many shares outstanding does Unity Biotechnology have?

Unity Biotechnology has 17,212,172 shares outstanding.

What happened to Unity Biotechnology’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Unity Biotechnology?

Currently, no hedge funds are holding shares in UNBX

Company Description

Unity Biotechnology

Unity Biotechnology, Inc. is a biotechnology firm developing therapies to slow, halt, or reverse aging-related diseases with programs like senolytic candidates targeting ophthalmologic and neurologic disorders.